A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab

Background: Immune responses play an important role in the development of breast cancer. Trastuzumab can activate antibody-dependent cellular cytotoxicity (ADCC) in human epidermal growth factor receptor-2 (HER-2)-positive breast cancer. Many studies have demonstrated that inflammatory markers, such...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Manag Res
Päätekijät: Hong, Jin, Chen, Xiaosong, Gao, Weiqi, Zhu, Siji, Wu, Jiayi, Huang, Ou, He, Jianrong, Zhu, Li, Chen, Weiguo, Li, Yafen, Fei, Xiaochun, Lin, Lin, Shen, Kunwei
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Dove 2019
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6497860/
https://ncbi.nlm.nih.gov/pubmed/31114373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S187233
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia